Titles
- CMC postapproval manufacturing changes for specified biological products to be documented in annual reports2
- CMS Innovation Center: model implementation and center performance : report to Congressional requesters1
- CMS can do more to leverage Medicare claims data to identify unreported incidents of potential abuse or neglect1
- CMS could improve the data it uses to monitor antipsychotic drugs in nursing homes1
- CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities1
- CMS has opportunities to strengthen states’ oversight of Medicaid Managed Care Plans’ reporting of medical loss ratios1
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- CMS should pursue strategies to increase the number of at-risk beneficiaries acquiring naloxone through Medicaid1
- CMS should take further action to address states with poor performance in conducting nursing home surveys1
- CMS use of data on nursing home staffing: progress and opportunities to do more1
- CMS validated hospital inpatient quality reporting program data, but should use additional tools to identify gaming1
- CMS's 2018 proposed Medicaid managed care rule: a summary of major provisions1
- CMS's final rule on Medicaid managed care: a summary of major provisions1
- CMS’s encounter data lack essential information that Medicare Advantage organizations have the ability to collect1
- COVID-19 & veterans’ mental health fact sheet1
- COVID-19 Provider Relief Fund: HRSA continues to recover remaining payments due from providers : report to congressional committees1
- COVID-19 and affordability of coverage and care for Medicare beneficiaries1
- COVID-19 and nursing home residents1
- COVID-19 antivirals utilization: geographic and demographic patterns of treatment in 20221
- COVID-19 cases and deaths, metropolitan and nonmetropolitan counties over time: (update)1